A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the european medicines agency guidelines
Impacto
Scholar |
Otros documentos de la autoría: Garrido Cano, Iris; García García, Aurelio; Vives-Peris, Vicente; Ochoa Aranda, Enrique; Esteve-Romero, Josep
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/7013
comunitat-uji-handle3:10234/8638
comunitat-uji-handle4:
INVESTIGACIONEste recurso está restringido
http://dx.doi.org/10.1016/j.talanta.2015.07.078 |
Metadatos
Título
A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the european medicines agency guidelinesAutoría
Fecha de publicación
2015-11Editor
ElsevierCita bibliográfica
GARRIDO-CANO, Iris, et al. A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the European Medicines Agency guidelines. Talanta, 2015, vol. 144, p. 1287-1295.Tipo de documento
info:eu-repo/semantics/articleVersión de la editorial
http://www.sciencedirect.com/science/article/pii/S0039914015302046Versión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
A procedure based on micellar liquid chromatography has been developed to monitor five tyrosine kinase inhibitors in plasma, prescribed against several kinds of cancer: erlotinib, imatinib, sunitinib, sorafenib and ... [+]
A procedure based on micellar liquid chromatography has been developed to monitor five tyrosine kinase inhibitors in plasma, prescribed against several kinds of cancer: erlotinib, imatinib, sunitinib, sorafenib and lapatinib. The sample was diluted in a micellar solution and directly injected, thus clean-up steps were not required. The analytes were resolved without interferences in <20 min using a C18 column and a mobile phase of 0.13 M SDS-4% 1-butanol, buffered at pH 3.5, running under isocratic mode at 1 mL/min. The detection was performed by UV–visible absorbance, using a wavelength program to maximize the signal-to-noise ratio. The method was validated following the guideline of the European Medicines Agency in terms of: selectivity, calibration range (0.05–5 μg/mol), linearity (r2>0.990), limit of detection (15–35 ng/mL), carry-over effect, accuracy (−10.4 to +11.0%), precision (<9.2%), matrix effect, robustness (<8.4%) and stability. The procedure is rapid, easy-to-handle, uses a low amount of toxic chemical provide reliable results. Finally, the method was successfully used to analyze the studied tyrosine kinase inhibitors in plasma from cancer patients. [-]
Publicado en
Talanta Volume 144, 1 November 2015Derechos de acceso
Copyright © 2015 Elsevier B.V. All rights reserved.
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
Aparece en las colecciones
- QFA_Articles [817]